Patents by Inventor David F. Mercer

David F. Mercer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Animal model having a chimeric human liver
    Patent number: 7498479
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 3, 2009
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Animal model having a chimeric human liver
    Patent number: 7161057
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: January 9, 2007
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection
    Publication number: 20030115616
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Application
    Filed: September 12, 2002
    Publication date: June 19, 2003
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Chimeric animal model susceptible to human hepatitis C virus infection
    Patent number: 6509514
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: January 21, 2003
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer